
Merlintrader Trading Pub
Biotech catalyst, news and analysis PDUFA tracker

Merlintrader Trading Pub
Biotech catalyst, news and analysis PDUFA tracker
AI transparency: articles and reports are produced with the help of artificial intelligence and checked through a process that does not constitute specialist validation. They may contain errors: verify relevant information with independent sources. Read the full disclaimer.
Nov 10, 2026
Tyra Biosciences reported third quarter 2026 net loss of $51.1 million and cash of $700.5 million as of September 30, 2026.
$TYRABiotech · Precision medicineDated financialsExecution and funding risk
TYRA Stock Hub: Tyra Biosciences News, Operations and Capital
BEACH301, the oncology evidence, an earlier oral competitor and the economic shares behind the financing. The November 9, 2026 regular-session close was $22.30. Third-quarter 2026 results, filed on November 10, show $700.5 million of cash and marketable securities at September 30; historical financial and clinical observations retain the dates shown below.
Full research report · PDF
Tyra Biosciences ($TYRA), research as of October 12, 2026
16 pages covering This archive explains dabogratinib’s pediatric sentinel dataset, the larger BEACH301 study and the revised timing for initial results. It examines height-velocity limitations, competing oral therapy, the oncology program and financing, including common shares and pre-funded equivalents. This is dated research; the hub follows later developments. For personal use only: redistribution prohibited.
Next financial and operating checkpoint
2027 · BEACH301 sentinel data
Initial open-label Phase 2 results from the safety sentinel cohort, approximately 25 children in aggregate, are expected in 2027, including six-month annualized height velocity and safety. The Data Safety Monitoring Committee has authorized a sixth dose level at 0.875 mg/kg in the sentinel cohort. Third-quarter 2026 report, November 10
The November 10 report guides these results to 2027 and does not repeat the end-of-Q1 2027 timing given in the August update, which had itself superseded the older Q4 2026 window. BridgeBio’s February 4 FDA target is an external competitive event, not a TYRA approval decision; SURF302 initial results are already historical. Before then, Tyra holds one-on-one investor meetings at the Guggenheim Healthcare Innovation Conference in Boston on November 10 and gives a hybrid presentation at the Jefferies Global Healthcare Conference in London on Monday, November 16 at 11:30 a.m. GMT (6:30 a.m. ET), webcast on the company’s investor page. November 5 announcement
TYRA stock at a glance
Close · November 9, 2026
$22.30
Regular session; +5.44% versus $21.15 on November 6.
Market snapshot
Oct 9 close $19.94; common-share market cap ~$1.37B
Historical observation in the source report; its stated financial or clinical date applies.
Pro forma economic base
84.54M shares: 69.08M common (November 6) plus 15.46M pre-funded warrants (September 30)
Source; sum calculated by Merlintrader.
Initial sentinel dataset
~25 children
Company-planned initial dataset; distinct from the full BEACH301 study.
Where Tyra Biosciences stands now
On November 10, 2026 Tyra reported third-quarter results: cash, cash equivalents and marketable securities were $700.5 million at September 30, against total liabilities of $34.7 million. Third-quarter R&D expenses were $43.1 million (from $25.5 million a year earlier), G&A $11.7 million (from $7.5 million) and net loss $51.1 million (from $29.9 million). Over nine months the net loss was $136.0 million and operating cash use $95.9 million. Management now expects the September 30 balance to fund planned operations through 2030, a company forecast that replaces the earlier June-based runway into the second half of 2028. Third-quarter 2026 results Third-quarter 2026 Form 10-Q The September offering closed on September 15: 9,079,000 common shares at $22.03 and pre-funded warrants for 9,078,529 shares at $22.029, for net proceeds of $376.2 million. All of the new pre-funded warrants went to an existing stockholder affiliated with a board member; a Form 4 filed September 17 by RA Capital reports that purchase. At September 30, 15,460,479 pre-funded warrants with a $0.001 exercise price remained outstanding, and 69,082,747 common shares were outstanding at November 6: together an economic base of 84,543,226 shares before options and RSUs (Merlintrader calculation). No shares had been sold at September 30 under the at-the-market program with $250.0 million of capacity. Clinically, the 60 mg SURF302 cohort is fully enrolled, a 70 mg cohort is enrolling, and Tyra plans to engage health authorities on a Phase 3 adjuvant study in intermediate-risk non-muscle invasive bladder cancer expected to start in 2027, subject to regulatory feedback. RA Capital Form 4, filed September 17, 2026 September offering prospectus September financing Form 8-K
The main constraint. The contrary case is that early activity fails to establish a usable chronic or registrational profile. The pediatric dataset is small and open-label; growth velocity is not final height or broader health benefit. An oral competitor is already in FDA review ahead of the readout. The cancer program must translate lesion response into a meaningful later study, and the financing expands the economic denominator through pre-funded warrants. BridgeBio infigratinib FDA review update September clinical update filed with SEC September offering prospectus
The constructive case
The constructive case is that selective oral FGFR3 inhibition can produce useful activity in distinct settings: recurrent urothelial disease and genetically defined pediatric growth disorders. Initial SURF302 results support further oncology work, while BEACH301 can test human growth proof of concept. A coherent efficacy and safety balance plus adequate resources could support a broader franchise. Each indication still needs its own evidence and regulatory path. With $700.5 million at September 30 and company runway guidance through 2030, financing pressure is lower than before the September offering, and a Phase 3 adjuvant study is planned to start in 2027, subject to regulatory feedback. September clinical update filed with SEC BEACH301 trial registry Third-quarter 2026 results
The cautious case
The contrary case is that early activity fails to establish a usable chronic or registrational profile. The pediatric dataset is small and open-label; growth velocity is not final height or broader health benefit. An oral competitor is already in FDA review ahead of the readout. The cancer program must translate lesion response into a meaningful later study, and the financing expands the economic denominator through pre-funded warrants. The quarterly net loss rose to $51.1 million in the third quarter, the runway through 2030 is a company forecast, and the BEACH301 sentinel readout is now guided only to 2027. BridgeBio infigratinib FDA review update September clinical update filed with SEC September offering prospectus
Latest Tyra Biosciences news
Nov 10, 2026
Tyra Biosciences Reports Third Quarter 2026 Financial Results and Recent Highlights
Tyra Biosciences reported a third quarter 2026 net loss of $51.1 million, compared with $29.9 million for the same period in 2025. Cash, cash equivalents and marketable securities were $700.5 million as of September 30, 2026, and the company expects them to fund planned operations through 2030 following a $400 million financing. Initial Phase 2 SURF302 results for oral dabogratinib showed a 79% ORR and 64% BOR CR rate at 60 mg QD among 14 participants with single and multiple marker lesions. R&D expenses were $43.1 million versus $25.5 million, and G&A expenses were $11.7 million versus $7.5 million.
Nov 5, 2026
Tyra Biosciences to participate in upcoming investor conferences
Tyra Biosciences will attend the Guggenheim 3rd Annual Healthcare Innovation Conference 2026 for one-on-one investor meetings on November 10, 2026, in Boston, MA. It will also take part in the Jefferies Global Healthcare Conference in London on November 16, 2026, with a hybrid presentation and one-on-one investor meetings. A live webcast of the Jefferies presentation will be available on the For Investors page of the Tyra Biosciences website and for replay after the event.
Oct 27, 2026
Black Rock reporting-unit ownership amendment filed
Black Rock reported 3,304,658 shares, or 4.8%, as of September 30. The ordinary-course filing describes specified business-unit scope, with no control purpose; it is not financing proceeds or a clinical result.
Oct 6, 2026
competitive update
October 6, 2026 — competitive update: Bridge Bio announced NDA acceptance and priority review for oral infigratinib, with a February 4, 2027 target action date. This external event sharpens the differentiation question for Tyra's pediatric program. Bridge Bio infigratinib FDA review update
Sep 21, 2026
Dated institutional ownership disclosed
The SCHEDULE 13G filing dated September 21, 2026 is part of the dated public record underlying this report. Filing status is distinct from a completed financing, regulatory approval or a subsequent operating outcome.
Sep 17, 2026
financing terms
September 14–15, 2026 — financing terms: Tyra priced an offering of 9,079,000 common shares and pre-funded warrants for 9,078,529 shares, for roughly $400 million gross proceeds. Settlement on September 15 is reflected in RA Capital's Form 4, which reports its purchase of all the pre-funded warrants on that date. RA Capital Form 4, filed September 17, 2026 September financing pricing announcement September financing Form 8-K
TYRA stock catalysts: operating and financial milestones
- November 10, 2026 — Third-quarter 2026 results and Form 10-Q: $700.5 million of cash and marketable securities at September 30; runway guidance through 2030. Completed · company report
- November 10, 2026 — One-on-one investor meetings at the Guggenheim 3rd Annual Healthcare Innovation Conference, Boston. Investor conference · announced November 5
- November 16, 2026 · 11:30 a.m. GMT (6:30 a.m. ET) — Hybrid presentation and one-on-one meetings at the Jefferies Global Healthcare Conference in London; live webcast and replay on the company’s investor page. Investor conference · announced November 5
- 2027 — BEACH301 sentinel dataset, approximately 25 children in aggregate, after a sixth dose level (0.875 mg/kg) was authorized. Company early-data target; the end-of-Q1 2027 timing given in August was not repeated on November 10
- February 4, 2027 — BridgeBio infigratinib FDA target action. External competitive event; not TYRA FDA review
- 2027 — SURF303 initial results. Company window without a fixed day
- 2027 — Planned initiation of a Phase 3 adjuvant study in intermediate-risk non-muscle invasive bladder cancer, subject to regulatory feedback, and additional SURF302 ablative results. Company plan
October 6, 2026 disclosure September 21, 2026 disclosure September 17, 2026 disclosure November 5, 2026 conference schedule November 10, 2026 third-quarter report
A precision-medicine business with one central clinical dependency
Tyra Biosciences is a clinical-stage company focused on fibroblast growth factor receptor biology. Its lead candidate is oral dabogratinib, formerly TYRA-300, a selective FGFR3 inhibitor being developed in urothelial cancers and achondroplasia. The company is based in Carlsbad, California, incorporated in Delaware, and trades on the Nasdaq Global Select Market as TYRA. It has not generated product revenue. The investment debate is about the value of a development portfolio, not the profitability of an existing commercial medicine. June 2026 Form 10-Q The appeal of the lead asset is that the same biological target matters in more than one disease context. That can create multiple development opportunities without inventing an unrelated molecule for every indication. It also creates concentration. A compound-specific safety or pharmacology issue can affect more than one program, while a strong result in one setting does not automatically establish the benefit-risk balance in another. An adult oncology population and children requiring long-term treatment are materially different clinical settings.
SNÅP and the difficulty of receptor selectivity
Tyra’s SNÅP platform uses iterative molecular structural information to guide drug design. The company describes a process intended to improve potency, selectivity and tolerability against closely related FGFR targets. The scientific problem is not simply finding a molecule that inhibits a receptor. It is finding a compound that meaningfully inhibits the intended receptor at achievable exposure while limiting unwanted effects on related receptors and other biological systems. This is the claimed enabling role of the platform. 2025 Form 10-K Selectivity is important because members of the FGFR family participate in physiological processes as well as disease signaling. Tyra’s filings discuss adverse effects associated with broader receptor inhibition and the rationale for separating FGFR3 activity from activity at other isoforms. The platform’s laboratory results can support a mechanistic hypothesis, but the clinically relevant selectivity must still be demonstrated through human exposure, pharmacodynamic effects and observed adverse events. An attractive biochemical ratio is not a substitute for that therapeutic window.
Merlintrader Health Score · $TYRA
3.20out of 5
Assessed on November 10, 2026, on financial filings through September 30 (third-quarter Form 10-Q), company announcements through November 10 and short-interest data through the October 15 settlement. Balance sheet raised from 4.5 to 5.0 after the post-offering balance was reported; other pillar scores unchanged from the October 31 assessment. Weighted calculation: 5.0×30% + 3.0×30% + 1.5×20% + 1.5×10% + 3.5×10% = 3.20. The score describes financial and operational robustness over twelve to eighteen months. It is not a rating, a target price or a recommendation.
Red flags
- Historical cash is not a current cash balance; subsequent spending and financing matter.
- Company milestones remain conditional where explicitly identified as plans or targets.
- The November 10 report guides BEACH301 sentinel results only to 2027, without the end-of-Q1 2027 timing given in August.
- The contrary case is that early activity fails to establish a usable chronic or registrational profile. The pediatric dataset is small and open-label; growth velocity is not final height or broader health benefit. An oral competitor is already in FDA review ahead of the readout. The cancer program must translate lesion response into a meaningful later study, and the financing expands the economic denominator through pre-funded warrants. BridgeBio infigratinib FDA review update September clinical update filed with SEC September offering prospectus
TYRA Stock FAQ: Tyra Biosciences Questions Answered
When will Tyra report BEACH301 results?
Tyra’s November 10, 2026 third-quarter report guides initial BEACH301 safety-sentinel results to 2027, covering approximately 25 children in aggregate; the August 4 outlook had indicated the end of Q1 2027. A sixth dose level at 0.875 mg/kg has been authorized in the sentinel cohort. The planned update includes six-month annualized height velocity and safety. It is an initial open-label Phase 2 dataset within the larger study, with no exact publication day announced. Sentinel dataset, measures and current timing. BEACH301 design and study scope.
Is Tyra’s dabogratinib FDA approved?
No: as of November 10, 2026, dabogratinib remained an investigational treatment in Tyra’s clinical development programs for achondroplasia and urothelial cancers. Orphan Drug and Rare Pediatric Disease designations for achondroplasia do not constitute marketing approval. Each indication requires its own clinical evidence and regulatory process, including an adequate assessment of safety and benefit. Investigational programs and regulatory designations. Clinical-stage development and initial oncology results.
How much cash does Tyra Biosciences have, and how long will it last?
Tyra reported US$700.5 million of cash, equivalents and marketable securities at September 30, 2026, after US$376.2 million of net proceeds from the September offering, with US$95.9 million of operating cash use in the first nine months. The company expects that balance to fund planned operations through 2030; this is a company forecast and replaces the August guidance into the second half of 2028. September liquidity and runway guidance. Nine-month operating cash flow and offering proceeds. Estimated offering proceeds after expenses. September purchase and settlement record.
How did Tyra’s September offering dilute TYRA shareholders?
Tyra’s September 14, 2026 prospectus offered 9,079,000 common shares and pre-funded warrants for another 9,078,529 shares. It also disclosed older pre-funded warrants covering 6,381,950 shares at June 30; at September 30 the 10-Q reported 15,460,479 pre-funded warrants outstanding in total, with no exercises during the first nine months. Their nominal US$0.001 exercise price means the economic share base extends beyond common shares alone. Options and restricted stock units add further potential shares, so common-share market capitalization uses a narrower denominator. New common shares, pre-funded warrants and excluded equity instruments.
When does Tyra Biosciences report earnings?
Tyra reported third-quarter 2026 results on November 10, 2026, for the quarter ended September 30; as of that date the next quarterly report date had not been announced. The BEACH301 data window in 2027 concerns a clinical update, rather than a scheduled quarterly financial report. Current company announcements. Latest financial results and clinical data outlook.
What does Tyra Biosciences do?
As of November 10, 2026, Tyra Biosciences develops precision medicines targeting fibroblast growth factor receptor biology. Its lead oral drug candidate, dabogratinib, formerly TYRA-300, selectively targets FGFR3 and is being studied in achondroplasia and urothelial cancers. Tyra is a clinical-stage business, using its SNÅP drug-design platform to advance candidate medicines rather than selling an approved commercial product. Company, lead candidate and development programs. Business stage and financial reporting.
Is Tyra’s full BEACH301 study only 25 children?
No: the BEACH301 registry updated October 1, 2026 lists estimated enrollment of 92 participants for the overall study. Approximately 25 children refers to Tyra’s planned initial safety-sentinel dataset, with results expected in 2027. The overall Phase 2 study is open-label and has later scheduled endpoints, so the early cohort and full study have different scopes. Estimated full-study enrollment, update date and open-label design. Initial sentinel cohort and data window.
Will Tyra’s early BEACH301 growth data prove final adult height?
No: Tyra’s planned 2027 BEACH301 update measures early annualized height velocity and safety, not final adult height. Persistence of growth and longer-term health outcomes require longer observation. For context, FDA’s accelerated approval of the separate medicine Yuviwel was based on growth velocity and requires a study confirming final adult height; that approval does not apply to dabogratinib. Planned early growth and safety observations. Growth-velocity basis and final-height confirmation requirement.
Primary sources
- November 10, 2026 — Third-quarter 2026 results and recent highlights
- November 10, 2026 — Form 10-Q for the quarter ended September 30, 2026
- November 5, 2026 — Investor conferences: Guggenheim meetings November 10; Jefferies London presentation November 16, 11:30 a.m. GMT
- October 27, 2026 — BlackRock reporting-unit ownership amendment filed
- October 6, 2026 — competitive update
- September 21, 2026 — Dated institutional ownership disclosed
- September 17, 2026 — financing terms
- September 17, 2026 — Insider transaction disclosed in a Form 4
- September 9, 2026 — clinical update
Disclaimer. This content is published by Merlintrader for educational and informational purposes only. It is independent educational research. It does not constitute investment advice, an investment recommendation, an offer or a solicitation to buy or sell any security, and it is not a research report within the meaning of applicable United States securities regulation. Nothing here should be read as a recommendation to buy, sell or hold $TYRA or any other security.
Figures are taken from public filings with the U.S. Securities and Exchange Commission, company press releases and market-data providers, and are stated with their reference dates. Data can change without notice, and figures published before a results release become outdated the moment that release is issued. Merlintrader makes no representation that the information is complete or current at the time of reading. Readers should verify every figure against the primary source before acting on it.
Biotechnology companies carry clinical, regulatory, manufacturing, commercial and financing risks. Trial results may not support approval; company milestones may move; safety or efficacy can disappoint. Approval does not guarantee adoption or profitable sales. Further borrowing or share issuance can increase obligations or dilute holders. Investors can lose part or all of their capital. Every reader is responsible for their decisions and should consult a licensed financial adviser where appropriate.
Merlintrader may hold positions in securities mentioned. Some links on this page are affiliate or referral links, including those to Finviz and Stocktwits, which may generate a commission at no cost to the reader. Full legal information is available on the disclaimer and terms of use and privacy pages.



